Zurück zur Übersicht
| Bone marrow transplantation. 2014 Mar 31. pii: bmt201439. doi: 10.1038/bmt.2014.39 |
| Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. |
| Mohty M1, Hübel K2, Kröger N3, Aljurf M4, Apperley J5, Basak GW6, Bazarbachi A7, Douglas K8, Gabriel I9, Garderet L10, Geraldes C11, Jaksic O12, Kattan MW13, Koristek Z14, Lanza F15, Lemoli RM16, Mendeleeva L17, Mikala G18, Mikhailova N19, Nagler A20, Schouten HC21, Selleslag D22, Suciu S23, Sureda A24, Worel N25, Wuchter P26, Chabannon C27, Duarte RF28 |
 Author information
|
|
Abstract Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents. |
|
Publikations ID: 24686988 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
